Jeffrey W.  Sherman net worth and biography

Jeffrey Sherman Biography and Net Worth

Dr. Jeffrey W. Sherman joined Horizon in June 2009 as executive vice president, development and regulatory affairs and chief medical officer and throughout his time at Horizon has assumed various responsibilities in addition to chief medical officer.

Before joining Horizon, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. Before IDM Pharma, he served as vice president of clinical science at Takeda Global Research and Development and from September 2000 to June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm Inc. From October 1992 to August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle. Dr. Sherman started in industry at Squibb/Bristol-Myers Squibb from April 1988 to September 1992 in clinical pharmacology and clinical research.

Dr. Sherman currently serves as a Drug Information Association (DIA) liaison to the Clinical Trial Transformation Initiative (CTTI), a public-private partnership founded by the U.S. Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. From June 2009 to June 2010 he served as president and board member of the DIA. He also serves on the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process.

Dr. Sherman is a member of the Global Genes Medical and Scientific Advisory Board and involved with the National Organization for Rare Disorders (NORD) and the European Organisation for Rare Diseases (EURORDIS). He is also an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman also serves on the boards of directors of Strongbridge Biopharma and Xeris Pharmaceuticals.

Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.

What is Jeffrey W. Sherman's net worth?

The estimated net worth of Jeffrey W. Sherman is at least $628,020.00 as of November 27th, 2023. Dr. Sherman owns 5,400 shares of Horizon Therapeutics Public stock worth more than $628,020 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Sherman may own. Learn More about Jeffrey W. Sherman's net worth.

How do I contact Jeffrey W. Sherman?

The corporate mailing address for Dr. Sherman and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Jeffrey W. Sherman's contact information.

Has Jeffrey W. Sherman been buying or selling shares of Horizon Therapeutics Public?

Jeffrey W. Sherman has not been actively trading shares of Horizon Therapeutics Public during the past quarter. Most recently, Jeffrey W. Sherman sold 3,368 shares of the business's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $113.05, for a transaction totalling $380,752.40. Following the completion of the sale, the executive vice president now directly owns 39,539 shares of the company's stock, valued at $4,469,883.95. Learn More on Jeffrey W. Sherman's trading history.

Who are Horizon Therapeutics Public's active insiders?

Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Jeffrey W. Sherman Insider Trading History at Horizon Therapeutics Public

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2023Sell3,368$113.05$380,752.4039,539View SEC Filing Icon  
1/6/2023Sell5,187$113.29$587,635.2349,314View SEC Filing Icon  
12/12/2022Sell28,352$111.45$3,159,830.4054,501View SEC Filing Icon  
4/6/2022Sell42,009$110.02$4,621,830.1810,629View SEC Filing Icon  
9/21/2021Sell46,271$110.00$5,089,810.00View SEC Filing Icon  
12/7/2020Sell63,078$70.94$4,474,753.3228,015View SEC Filing Icon  
7/6/2020Sell9,100$57.50$523,250.00View SEC Filing Icon  
5/11/2020Sell33,479$45.00$1,506,555.0047,445View SEC Filing Icon  
8/2/2016Sell2,900$20.00$58,000.00View SEC Filing Icon  
2/26/2016Sell4,100$20.00$82,000.00149,648View SEC Filing Icon  
12/10/2015Sell4,456$20.00$89,120.00105,132View SEC Filing Icon  
9/21/2015Sell7,750$31.78$246,295.00105,132View SEC Filing Icon  
7/15/2015Sell26,887$35.55$955,832.85View SEC Filing Icon  
11/19/2014Sell24,999$12.05$301,237.95View SEC Filing Icon  
See Full Table

Jeffrey W. Sherman Buying and Selling Activity at Horizon Therapeutics Public

This chart shows Jeffrey W Sherman's buying and selling at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $116.30
Low: $116.30
High: $116.30

50 Day Range

MA: $115.72
Low: $112.60
High: $116.30

2 Week Range

Now: $116.30
Low: $60.03
High: $116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03